{"id":"NCT03533114","sponsor":"Jazz Pharmaceuticals","briefTitle":"A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension","officialTitle":"A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-11-27","primaryCompletion":"2020-06-12","completion":"2020-12-18","firstPosted":"2018-05-22","resultsPosted":"2021-11-24","lastUpdate":"2021-11-24"},"enrollment":154,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Idiopathic Hypersomnia"],"interventions":[{"type":"DRUG","name":"JZP-258","otherNames":[]},{"type":"DRUG","name":"Placebo Oral Solution","otherNames":[]}],"arms":[{"label":"JZP-258","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study of the efficacy and safety of JZP-258, an oxybate mixed-salts oral solution being developed as a low sodium alternative product for Xyrem.","primaryOutcome":{"measure":"Change in Epworth Sleepiness Scale (ESS) Score","timeFrame":"Change from the end of the Stable Dose Period to the end of the Double-blind Randomized Withdrawal Period (DBRW) (2 Weeks)","effectByArm":[{"arm":"JZP-258","deltaMin":0.7,"sd":3.22},{"arm":"Placebo","deltaMin":7.4,"sd":5.16}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":63,"countries":["United States","Belgium","Czechia","Finland","France","Poland","Spain","United Kingdom"]},"refs":{"pmids":["40135693","37409509","34942138"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":88},"commonTop":["Nausea","Headache","Dizziness","Vomiting","Anxiety"]}}